1 new product(s) added recently

State of the Art Course in Addiction Medicine 2024

Product not yet rated

  • Register
    • Non-Member - $329
    • Regular Member - $249
    • Retired - $249
    • Early Career Physician - $249
    • Resident - $169
    • Student - $169
    • Associate - $169
    • ASAM Staff - Free!
    • International Member - $249
    • Emeritus Member - $249
    • Provisional Member - $249
    • Fellow Member - $249
    • Honorary Member - $249
    • CRT Member - $249
image

ASAM State of the Art Course Addiction Medicine 2024

Recorded on Thursday, October 17 - Friday, October 18, 2024

On-Demand Course

Overview

This 16-hour live course includes 9 sessions highlighting best practices and the latest science, research, and innovations in addiction medicine from leading experts in the field.

These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:

  • Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
  • Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
  • Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine

This conference addresses all 6 ACGME Competencies.

Learning Objectives

At the end of the course, learners should be able to:

  1. Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
  2. Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
  3. Develop practical applications for integrating new and emerging science into practice.
  4. Identify gaps in the field of addiction medicine that future research can address.
  5. Create a network of colleagues and resources to support the learner’s practice or form future research collaborations.

Registration Rates

ASAM Learner TypeRate
ASAM Member$249
Non-Member$329
Associate Member$169
Resident Member*$169
Student Member*$169

*Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.

Membership Question?  Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.

Refunds & Cancellations

All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.

Registration Open: 11/01/2024 - 10/01/2027

User Access Closed: 11/01/2027

Instructions

  1. Click on the Content tab to view all sessions within the course. Click the View button to access a specific session.
  2. Within each session, select the Content tab to begin the activity.
  3. Participants will need to complete posttests and evaluations after each session. Participants will have 10 attempts to pass and must answer 2 out of 3 questions correctly. Medical Credits are claimed within each session and are not available for the entire package.

Need Assistance?

For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org

ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.

Accreditation & Credits


Joint Accreditation Statement
image

In support of improving patient care, the American Society of Addiction Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credits Available
  • Physicians: 16 Credit(s)
  • Nurses & NPs: 16 Nursing Contact Hour(s)
  • Pharmacology Hour(s): 6.5 Hour(s)
  • PAs: 16 Credit(s)
  • Pharmacists: 16 Credit(s)
  • Interprofessional Continuing Education: 16 Credit(s)
  • Certified Counselors: NBCC Contact Hours Not offered

Maintenance of Certification (MOC)/Continuing Certification Program (CCP)

This activity is designed to meet the requirements for MOC/CCP for several primary physician boards and for state licensing CME requirements. MOC Credit is only reported and designated for ABA, ABP, ABIM, and ABS. By completing the online credit application and evaluation, the learner permits ASAM to report credits to the appropriate Board. Learn more.

  • ABA MOCA 2.0®*: 16 Lifelong Learning
  • ABIM MOC Points: 16 Medical Knowledge
  • ABP MOC: 16 Lifelong Learning & Self-Assessment
  • ABS Continuing Certification: 16 Accredited CME | 16 Self-Assessment

Additionally, this activity has been designed to satisfy the requirements of the following primary physician board certification requirements. Please confirm with your individual Board.

  • American Board of Addiction Medicine (ABAM)
  • American Board of Preventative Medicine (ABPM)
  • American Board of Psychiatry and Neurology (ABPN)
  • Royal College of Physicians and Surgeons of Canada (RCPSC)
Certificates for other professions

All participants may request a certificate of participation upon completion of the activity and an online evaluation confirming their participation. Learners are strongly advised to contact their professional licensing board or professional association to confirm this certificate will be accepted as evidence supporting continuing education requirements.

California Association for Drug/Alcohol Educators (CAADE)

This educational program is approved by CAADE: #CP40 999 1225.

California Association of DUI Treatment Centers (CADTP)

This educational program is approved by CADTP: #205.

California Consortium of Addiction Programs and Professionals (CCAPP)

This educational program is approved by CCAPP: #OS-20-330-1224.

Disclosure Information


In accordance with the disclosure policies of ASAM and Joint Accreditation, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all accredited continuing education activities. These policies include identifying and mitigating all relevant financial relationships with ineligible companies for those involved in the creation and dissemination of accredited continuing education.

See the attached pdf for a list of disclosures.


image

  American Society of Addiction Medicine has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 7062. Programs that do not qualify for NBCC credit are clearly identified. American Society of Addiction Medicine is solely responsible for all aspects of the programs.

MOCA 2.0® is a trademark of the American board of Anesthesiology®.
This activity contributes to the patient safety CME requirement for Part II: Lifelong Learning and Self-Assessment of the American board of Anesthesiology's (ABA) redesigned Maintenance of Certification in Anesthesiology Program® (MOCA®), known as MOCA 2.0®. Please consult the ABA website, https://www.theaba.org/, for a list of all MOCA 2.0 requirements.

The complete list of disclosures and designation statements are linked below.

Presenter Disclosures

  • Product not yet rated Contains 8 Component(s), Includes Credits

    This 2-hour, on-demand session from the 2024 ASAM State of the Art Course focuses on the prevention and treatment of stimulant use disorders and will discuss topics such as new clinical practice guidelines, novel pharmacotherapies, methamphetamine-induced psychotic disorders, and more.

    image

    Stimulants

    Recorded: Thursday, October 17, 2024 - Friday, October 18, 2024
    On-Demand Session

    Overview

    According to the CDC, from 2012 through 2020 in the United States, the number of deaths involving methamphetamine increased more than 6-fold while the number of deaths involving cocaine more than tripled. This session will focus on the prevention and treatment of stimulant use disorders and will discuss topics such as new clinical practice guidelines, novel pharmacotherapies, methamphetamine-induced psychotic disorders, and more. 

    This session is comprised of 4 presentations that deep dive into different aspects of the overall topic.

    • Novel Approaches to the Prevention and Treatment of Stimulant Use Disorders
      This presentation will summarize prevention and treatment recommendations from the new ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder. Key takeaways from the guideline will be discussed. Topics for discussion will include behavioral and pharmacological treatments, co-occurring conditions, management of stimulant intoxication and withdrawal, and secondary and tertiary prevention strategies to reduce harms associated with risky stimulant use.
    • Mosaic Approaches to Understanding ADHD and Stimulant Use Disorders
      This session provides an overview of ADHD, including diagnostic criteria and key characteristics, with a focus on understanding the overlap between ADHD and substance use disorders. Participants will explore methods to reduce stimulant misuse and examine the trajectories of substance use disorders in individuals with ADHD. The discussion will also highlight how the COVID-19 pandemic shifted diversion sources among adolescents and young adults, emphasizing the evolving nature of these challenges.
    • BEAT Meth: New Findings for Advancing Methamphetamine Addiction Treatment
      The pathophysiology of methamphetamine addiction--including its intense biological reinforcement and symptom profile--poses challenges for prevention and treatment. Attendees will hear original findings from BEAT Meth, a CDC-funded project that applies a multifaceted public health approach to addressing methamphetamine addiction. These findings include strategies to describe methamphetamine-related healthcare utilization; diagnostic criteria for methamphetamine-induced psychotic disorders; and adaptation of contingency management to support linkage to care.
    • Development of Dual-Acting Sigma and Dopamine Transporter Inhibitors as Potential Pharmacotherapy for Stimulant Use Disorders
      This session will describe a novel pharmacotherapy mechanism of treating stimulant use disorder.   The attendees will be able to explain the necessity for the dual mechanism of action in the drugs ability to attenuate rodents from self-administering cocaine.  This session will also demonstrate the success of this concept, the challenges that are still ahead with drug development, and the potential for this treatment to be game changing as an aid in the treatment of stimulant use disorders.

    These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:

    • Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
    • Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
    • Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine

    This conference addresses all 6 ACGME Competencies.

    Learning Objectives

    At the end of the course, learners should be able to:

    1. Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
    2. Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
    3. Develop practical applications for integrating new and emerging science into practice.
    4. Identify gaps in the field of addiction medicine that future research can address.
    5. Create a network of colleagues and resources to support the learner's practice or form future research collaborations.

    DEA Education Requirement

    As an accredited organization named in Section 1263 of the Consolidated Appropriations Act of 2023, ASAM certifies that completion of this course meets 2 hours of the DEA requirement for 8 hours of education on substance use disorder(s).

    Registration Rates

    ASAM Learner TypeRate
    ASAM Member$29
    Non-Member$39
    Associate Member$19
    Resident Member*$19
    Student Member*$19

    *Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.

    Membership Question?  Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.

    Refunds & Cancellations

    All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.

    Registration Open: 11/01/2024 - 10/01/2027

    User Access Closed: 11/01/2027

    Instructions

    1. Click on the Contents tab to begin this activity.
    2. Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
    3. Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
    4. Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.

    Need Assistance?

    For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org

    ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.

    Brian Hurley

    MD, MBA, DFASAM

    Brian Hurley, MD, MBA, DFASAM is an addiction physician and the Director of Addiction Medicine for the Los Angeles County Department of Health Services. Brian is currently a Director at Large for the American Society of Addiction Medicine (ASAM) and will assume the position of President-Elect this April 2021. He co-chairs the Los Angeles County Department of Health Services’ Substance Use Disorders Workgroup and the SafeMedLA Medications for Addiction Treatment Action Team, and is the Clinical Director of the Addiction Treatment Starts Here programs through the Center for Care Innovations, focused on increasing the delivery of Medications for Addiction Treatment in California’s community health centers. He is the PI of two MAT Access Points projects funded by the Sierra Health Foundation, a co-PI of a TRDRP funded smoking cessation implementation project, and a co-investigator on NIDA, NIAAA, and PCORI funded addiction related implementation science grants managed through RAND. He is a member of the Motivational Interviewing Network of Trainers and regularly conducts motivational interviewing trainings throughout the United States. He is a Volunteer Assistant Clinical Professor of Addiction Medicine in the Department of Family Medicine at the UCLA David Geffen School of Medicine. He additionally serves on the American Board of Psychiatry and Neurology’s Addiction Psychiatry examination writing committee.

     Brian completed the Robert Wood Johnson Foundation Clinical Scholars Program at the University of California, Los Angeles (UCLA), and was previously a UCLA - Veterans Administration National Quality Scholar at the VA Greater Los Angeles Healthcare System. He completed a fellowship program in addiction psychiatry at New York University School of Medicine. He completed residency training at the Massachusetts General Hospital and McLean Hospital, where he was Chief Resident in Addiction Psychiatry. Brian is a former National President of the American Medical Student Association.

    No relevant financial disclosures

    Vita V. McCabe, MD, MHSA, FACS, FCCP, FASAM

    Addiction Psychiatrist

    University of Michigan, Ann Arbor

    Dr. McCabe is a University of Chicago Medical School alumna and former cardiothoracic surgeon. She shifted her career focus after retiring due to physical health issues in 2015. 

    With a master’s in health management and policy from the University of Michigan School of Public Health, her expertise now spans physician systems change, impairment and resilience and is deeply influenced by her own personal journey with physical disability that affected her career as a surgeon and her family’s history of addiction.

    Dr. McCabe has made notable and significant contributions, including serving on the Illinois State Medical Board’s Impairment Council and chairing the Michigan’s Health Provider Assistance Committee which is the oversight body for the Health Professionals Recovery Program for 25 health professional boards. Her work has impacted policies on stimulants for the FDA and support systems for impaired physicians across six hospitals and within a national healthcare system. She has over 50 peer reviewed publications and her current research efforts focus on trajectories of SUD and ADHD.

    Dr. McCabe embraced her passion for mental health, completing her psychiatry residency and addiction psychiatry fellowship at the University of Michigan
    where she is a clinical associate professor of addiction psychiatry and is also boarded in addiction medicine.

    No relevant financial disclosures

    Alia Al-Tayyib, PhD

    Associate Research Scientist

    Denver Health

    Alia Al-Tayyib, PhD, MSPH, is an Associate Research Scientist at the Public Health Institute at Denver Health and an Associate Professor in the Department of Epidemiology at the Colorado School of Public Health. Dr. Al-Tayyib's primary research interests are in behavioral risks for acquiring and transmitting infections, such as HIV and hepatitis C, with a focus on the social and structural determinants of risk. Since 2007, she has served as the site PI for the National HIV Behavioral Surveillance (NHBS) system in the Denver metro area. More recently, Dr. Al-Tayyib has focused on social network studies examining the transition from oral ingestion of prescription opioids to injection drug use among at-risk youth and on developing interventions to keep people engaged in care for substance use disorders. The overarching goal of her work is to reduce the spread of infections, decrease substance use, and improve public health. Dr. Al-Tayyib currently leads the research efforts for the Denver Health Center for Addiction Medicine. She received her PhD and MSPH degrees in Epidemiology from the University of North Carolina at Chapel Hill and is an alumna of the Clinical Faculty Scholar and the Leadership for Innovative Team Science programs at the Colorado Clinical and Translational Sciences Institute.

    Christopher R. McCurdy, BSPh, PhD, FAAPS

    Professor

    University of Florida

    Dr. McCurdy serves as Associate Dean for Faculty Development and Professor in the Departments of Medicinal Chemistry and Pharmaceutics; and The Frank A. Duckworth Eminent Scholar Chair in Drug Research and Development at the University of Florida College of Pharmacy. He is also the Director of the UF Translational Drug Development Core. Dr. McCurdy completed his training as a pharmacist at Ohio Northern University and moved on to complete his PhD in medicinal chemistry from the University of Georgia, followed by a three-year postdoctoral fellowship at the University of Minnesota under Prof Philip Portoghese.  McCurdy began his academic career in 2001 at the University of Mississippi where he rose to the rank of full professor (with tenure).  He moved to the University of Florida in January of 2017.  His research focuses on the design, synthesis, and development of drugs to treat pain, anxiety, and substance use disorders. He is an internationally recognized expert on kratom (Mitragyna speciosa). He also has developed a PET/MR imaging diagnostic agent for visualizing the origins of chronic neuropathic pain. Phase 1 and 2 human clinical trials are currently underway.  He has published more than 200 manuscripts and holds 8 patents.  He is currently funded by multiple NIH grants and the Florida Department of Health. Dr. McCurdy serves as a consultant to the US Food and Drug Administration’s Drug Safety and Risk Management Advisory Committee and previously served as President of the American Association of Pharmaceutical Scientists (AAPS).

    No relevant financial disclosures

    Credits & Disclosures

    Joint Accreditation Statement

    image

    In support of improving patient care, the American Society of Addiction Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credits Available

    • Physicians: 2 Credit(s)
    • Nurses & NPs: 2 Nursing Contact Hour(s)
    • Pharmacology Hour(s): 1.75 Hour(s)
    • PAs: 2 Credit(s)
    • Pharmacists: 2 Credit(s)
    • Interprofessional Continuing Education: 2 Credit(s)
    • Certified Counselors: NBCC Contact Hours Not offered
    image American Society of Addiction Medicine has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 7062. Programs that do not qualify for NBCC credit are clearly identified. American Society of Addiction Medicine is solely responsible for all aspects of the programs.

    Maintenance of Certification (MOC)/Continuing Certification Program (CCP)

    This activity is designed to meet the requirements for MOC/CCP for several primary physician boards and for state licensing CME requirements. MOC Credit is only reported and designated for ABA, ABP, ABIM, and ABS. By completing the online credit application and evaluation, the learner permits ASAM to report credits to the appropriate Board. Learn more.

    • ABA MOCA 2.0®*: 2 Lifelong Learning
    • ABIM MOC Points: 2 Medical Knowledge
    • ABP MOC: 2 Lifelong Learning & Self-Assessment
    • ABS Continuing Certification: 2 Accredited CME | 2 Self-Assessment

    Additionally, this activity has been designed to satisfy the requirements of the following primary physician board certification requirements. Please confirm with your individual Board.

    • American Board of Addiction Medicine (ABAM)
    • American Board of Preventative Medicine (ABPM)
    • American Board of Psychiatry and Neurology (ABPN)
    • Royal College of Physicians and Surgeons of Canada (RCPSC)

    Certificates for other professions

    All participants may request a certificate of participation upon completion of the activity and an online evaluation confirming their participation. Learners are strongly advised to contact their professional licensing board or professional association to confirm this certificate will be accepted as evidence supporting continuing education requirements.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1225.

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205.

    California Consortium of Addiction Programs and Professionals (CCAPP)

    This educational program is approved by CCAPP: #OS-20-330-1224.

    MOCA 2.0® is a trademark of the American board of Anesthesiology®. This activity contributes to the patient safety CME requirement for Part II: Lifelong Learning and Self-Assessment of the American board of Anesthesiology's (ABA) redesigned Maintenance of Certification in Anesthesiology Program® (MOCA®), known as MOCA 2.0®. Please consult the ABA website, https://www.theaba.org/, for a list of all MOCA 2.0 requirements.

    Disclosure Information

    In accordance with the disclosure policies of ASAM and Joint Accreditation, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all accredited continuing education activities. These policies include identifying and mitigating all relevant financial relationships with ineligible companies for those involved in the creation and dissemination of accredited continuing education.

    See the attached pdf for a list of disclosures.

  • Product not yet rated Contains 5 Component(s), Includes Credits

    This 1-hour, on-demand session from the 2024 ASAM State of the Art Course covers most recent updates on emerging issues and advances in addiction medicine from the perspective of three major federal agencies: NIAAA, SAMHSA, and NIDA.

    image

    Federal Agency Session

    Recorded: Thursday, October 17, 2024 - Friday, October 18, 2024
    On-Demand Session

    Overview

    During this 1-hour, on-demand session from the 2024 ASAM State of the Art Course, federal agency leaders from NIAAA, SAMHSA, and NIDA give brief overviews about emerging issues and advances in addiction medicine from their respective organizations. Following the presentations, ASAM President, Dr. Brian Hurley, leads the agencies in a lively discussion about the most pressing topics in addiction medicine.

    These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:

    • Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
    • Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
    • Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine

    This conference addresses all 6 ACGME Competencies.

    Learning Objectives

    At the end of the course, learners should be able to:

    1. Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
    2. Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
    3. Develop practical applications for integrating new and emerging science into practice.
    4. Identify gaps in the field of addiction medicine that future research can address.
    5. Create a network of colleagues and resources to support the learner's practice or form future research collaborations.

    DEA Education Requirement

    As an accredited organization named in Section 1263 of the Consolidated Appropriations Act of 2023, ASAM certifies that completion of this course meets 2 hours of the DEA requirement for 8 hours of education on substance use disorder(s).

    Registration Rates

    ASAM Learner TypeRate
    ASAM Member$29
    Non-Member$39
    Associate Member$19
    Resident Member*$19
    Student Member*$19

    *Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.

    Membership Question?  Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.

    Refunds & Cancellations

    All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.

    Registration Open: 11/01/2024 - 10/01/2027

    User Access Closed: 11/01/2027

    Instructions

    1. Click on the Contents tab to begin this activity.
    2. Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
    3. Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
    4. Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.

    Need Assistance?

    For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org

    ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.

    George Koob

    PhD

    George F. Koob, PhD is Director of the National Institute on Alcohol Abuse and Alcoholism where he oversees a wide range of alcohol-related research, including genetics, neuroscience, epidemiology, prevention, and treatment. 

    As an authority on alcoholism, drug addiction and stress, he has contributed to our understanding of the neurocircuitry associated with the acute reinforcing effects of alcohol and drugs of abuse and the neuroadaptations of the reward and stress circuits associated with the transition to dependence. Dr. Koob has published over 750 peer reviewed papers and several books including the “Neurobiology of Addiction,” a comprehensive treatise on emerging research in the field, and a textbook for upper division undergraduates and graduate students called “Drugs, Addiction and the Brain.” He has mentored 12 PhD students, 84 post-doctoral fellows, and 11 K99’s.

    He received his PhD in Behavioral Physiology from Johns Hopkins University in 1972. He spent much of his early career at the Scripps Research Institute as the Director of the Alcohol Research Center, and as Professor and Chair of the Scripps’ Committee on the Neurobiology of Addictive Disorders. He has also served as a researcher in the Department of Neurophysiology at the Walter Reed Army Institute of Research and the Arthur Vining Davis Center for Behavioral Neurobiology at the Salk Institute for Biological Studies. Dr. Koob is the recipient of many honors, including membership in the National Academy of Medicine and award of the Legion of Honor (Knight of the Legion of Honor, France).

    Wilson Compton

    MD, MPE

    Wilson M. Compton, MD, MPE serves as the Deputy Director of the National Institute on Drug Abuse (NIDA) of the National Institutes of Health. In his current role, Dr. Compton's responsibilities include providing scientific leadership in the development, implementation, and management of NIDA's research portfolio and working with the Director to support and conduct research to improve the prevention and treatment of drug abuse and addiction. Prior to his current appointment, Dr. Compton served as the Director of NIDA's Division of Epidemiology, Services and Prevention Research from 2002 until 2013. In this leadership role, he oversaw the scientific direction of a complex public health research program of national and international scope addressing: 1) the extent and spread of drug abuse, 2) how to prevention drug abuse, and 3) how to implement drug abuse prevention and treatment services as effectively as possible. Before joining NIDA, Dr. Compton was Associate Professor of Psychiatry and Director of the Master in Psychiatric Epidemiology Program at Washington University in Saint Louis as well as Medical Director of Addiction Services at the Barnes-Jewish Hospital in Saint Louis. Dr. Compton received his undergraduate education from Amherst College. He attended medical school and completed his residency training in psychiatry at Washington University. During his career, Dr. Compton has achieved multiple scientific accomplishments: he was selected to serve as a member of the DSM-5 Revision Task Force; is the author of more than 130 articles and chapters; and is an invited speaker at multiple high-impact venues. Dr. Compton is the recipient of multiple awards and in 2008, he received the Senior Scholar Health Services Research Award from the American Psychiatric Association, in 2010 the Paul Hoch Award from the American Psychopathological Association, in both 2012 and 2013, he was selected to receive the Leveraging Collaboration Award from the Food and Drug Administration. In 2013, Dr. Compton received the prestigious Health and Human Services Secretary's Award for Meritorious Service.

    Does Disclose: 3M Companies: Ownership Interest includes stock, stock options, patent or other intellectual property; General Electric Co.: Ownership Interest includes stock, stock options, patent or other intellectual property Pfizer, Inc.: Ownership Interest includes stock, stock options, patent or other intellectual property.

    Yngvild Olsen

    MD, MPH, DFASAM

    Dr. Yngvild Olsen serves as the Acting Director for the Center for Substance Abuse Treatment (CSAT). She has a long history of working within the addiction treatment field to expand access to care and enhance quality. She began her career as the Medical Director for the Johns Hopkins Hospital’s outpatient substance use treatment services while a full-time Assistant Professor in the Department of Medicine at the Johns Hopkins School of Medicine. She subsequently served as the Deputy Health Officer for Maryland’s Harford County Health Department. She led a modernization of publicly funded substance use treatment services in collaboration with State and local partners. She next served as the Vice President of Clinical Affairs for the Baltimore Substance Abuse Systems, then the local addiction authority for Baltimore City. In that position, she played a central role in expanding buprenorphine treatment for opioid addiction in both specialty treatment and general ambulatory medical systems. Dr. Olsen has also served as Medical Consultant to the Maryland Behavioral Health Administration, a clinical expert to the Maryland Addiction Consultation Service at the University of Maryland School of Medicine, and an advisor on addiction interventions to the Baltimore City Health Department. From 2011 to 2021, she served as Medical Director for the Institutes for Behavior Resources/REACH Health Services, a comprehensive outpatient substance use disorder treatment program in Baltimore City. She has held numerous senior volunteer leadership positions in the field of addiction medicine, including vice president of the American Society of Addiction Medicine, president of the Maryland Association for the Treatment of Opioid Dependence, and president of the Maryland/DC Society of Addiction Medicine. She also has served on the boards of the National Council on Alcohol and Drug Dependence-Maryland, Stop Stigma Now, and as a clinical expert to the Providers Clinical Support System (PCSS).

    Credits & Disclosures

    Joint Accreditation Statement

    image

    In support of improving patient care, the American Society of Addiction Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credits Available

    • Physicians: 1.00 Credit(s)
    • Nurses & NPs: 1.00 Nursing Contact Hour(s)
    • Pharmacology Hour(s): Not offered
    • PAs: 1.00 Credit(s)
    • Pharmacists: 1.00 Credit(s)
    • Interprofessional Continuing Education: 1.00 Credit(s)
    • Certified Counselors: NBCC Contact Hours Not offered
    image American Society of Addiction Medicine has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 7062. Programs that do not qualify for NBCC credit are clearly identified. American Society of Addiction Medicine is solely responsible for all aspects of the programs.

    Maintenance of Certification (MOC)/Continuing Certification Program (CCP)

    This activity is designed to meet the requirements for MOC/CCP for several primary physician boards and for state licensing CME requirements. MOC Credit is only reported and designated for ABA, ABP, ABIM, and ABS. By completing the online credit application and evaluation, the learner permits ASAM to report credits to the appropriate Board. Learn more.

    • ABA MOCA 2.0®*: 1.00 Lifelong Learning
    • ABIM MOC Points: 1.00 Medical Knowledge
    • ABP MOC: 1.00 Lifelong Learning & Self-Assessment
    • ABS Continuing Certification: 1.00 Accredited CME | 1.00 Self-Assessment

    Additionally, this activity has been designed to satisfy the requirements of the following primary physician board certification requirements. Please confirm with your individual Board.

    • American Board of Addiction Medicine (ABAM)
    • American Board of Preventative Medicine (ABPM)
    • American Board of Psychiatry and Neurology (ABPN)
    • Royal College of Physicians and Surgeons of Canada (RCPSC)

    Certificates for other professions

    All participants may request a certificate of participation upon completion of the activity and an online evaluation confirming their participation. Learners are strongly advised to contact their professional licensing board or professional association to confirm this certificate will be accepted as evidence supporting continuing education requirements.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1225.

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205.

    California Consortium of Addiction Programs and Professionals (CCAPP)

    This educational program is approved by CCAPP: #OS-20-330-1224.

    MOCA 2.0® is a trademark of the American board of Anesthesiology®. This activity contributes to the patient safety CME requirement for Part II: Lifelong Learning and Self-Assessment of the American board of Anesthesiology's (ABA) redesigned Maintenance of Certification in Anesthesiology Program® (MOCA®), known as MOCA 2.0®. Please consult the ABA website, https://www.theaba.org/, for a list of all MOCA 2.0 requirements.

    Disclosure Information

    In accordance with the disclosure policies of ASAM and Joint Accreditation, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all accredited continuing education activities. These policies include identifying and mitigating all relevant financial relationships with ineligible companies for those involved in the creation and dissemination of accredited continuing education.

    See the attached pdf for a list of disclosures.

  • Product not yet rated Contains 6 Component(s), Includes Credits

    This 1-hour, on-demand session from the 2024 ASAM State of the Art Course outlines recent interesting findings and topics that have emerged, from differences in formulations and routes of administration to ways research may impact the future of policy.

    image

    Cannabis

    Recorded: Thursday, October 17, 2024 - Friday, October 18, 2024
    On-Demand Session

    Overview

    Cannabis is the most used federally illegal drug in the United States. With a growing market and shrinking perception of harm among the general population, the last several years have seen a steady increase in research on cannabis and its relative benefits and harms. This session will outline recent interesting findings and topics that have emerged, from differences in formulations and routes of administration to ways research may impact the future of policy.

    This session is comprised of 2 presentations and a panel that dive deep into different aspects of the overall topic.

    • Using Human Laboratory Studies to Characterize the Effects of Novel Cannabis Products, Formulations, and Routes of Administration
      This session will showcase data from the Johns Hopkins Cannabis Science Lab which conducts controlled human dosing studies to understand the effects of cannabis. Research projects presented include systematic studies to characterize the impact of dose, route of administration, and product formulation, as well as studies designed to determine driving impairment associated with cannabis use.
    • How Laboratory Science Can Inform Cannabis Use Prevention, Treatment, and Regulation
      This session will review current data on the use of cannabis in medical settings. These data will include an overview of the possible clinical benefits and adverse effects of cannabis. Topics covered will include drug-drug interactions with other medications, effects of acute and chronic cannabis on mental health and performance, and potential for abuse and dependence. Methods described will include laboratory assessments, real-world treatment tracking, and epidemiological data.

    These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:

    • Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
    • Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
    • Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine

    This conference addresses all 6 ACGME Competencies.

    Learning Objectives

    At the end of the course, learners should be able to:

    1. Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
    2. Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
    3. Develop practical applications for integrating new and emerging science into practice.
    4. Identify gaps in the field of addiction medicine that future research can address.
    5. Create a network of colleagues and resources to support the learner's practice or form future research collaborations.

    DEA Education Requirement

    As an accredited organization named in Section 1263 of the Consolidated Appropriations Act of 2023, ASAM certifies that completion of this course meets 2 hours of the DEA requirement for 8 hours of education on substance use disorder(s).

    Registration Rates

    ASAM Learner TypeRate
    ASAM Member$29
    Non-Member$39
    Associate Member$19
    Resident Member*$19
    Student Member*$19

    *Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.

    Membership Question?  Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.

    Refunds & Cancellations

    All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.

    Registration Open: 11/01/2024 - 10/01/2027

    User Access Closed: 11/01/2027

    Instructions

    1. Click on the Contents tab to begin this activity.
    2. Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
    3. Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
    4. Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.

    Need Assistance?

    For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org

    ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.

    Tory Spindle, PhD

    Assistant Professor

    Johns Hopkins University

    Dr. Tory Spindle obtained his PhD in Experimental Health Psychology from Virginia Commonwealth University. Broadly, Dr. Spindle utilizes human laboratory studies to characterize the behavioral pharmacology of cannabis and individual cannabis constituents. His research seeks to understand how factors such as route of administration (oral, vaped, smoked, topical), dose, product formulation/chemical composition profile, and user factors (e.g., puffing topography, sex, tolerance) impacts the pharmacokinetic and pharmacodynamic effects of cannabis. Another emphasis of his work is on characterizing cognitive, psychomotor, and driving impairment associated with cannabis, when used alone and in combination with alcohol. Overall, Dr. Spindle’s work is intended to inform policy decisions involving cannabis such as product standards and accessibility, dosing guidelines, and procedures for detecting cannabis impairment. Because the overarching goal of his research is to inform policies and regulatory actions for cannabis, his work can be best described as “cannabis regulatory science.”

    Does Disclose: Canopy Growth Corporation. Serve as a paid consultant

    Justin C. Strickland, PhD

    Associate Professor

    Johns Hopkins University School of Medicine

    Dr. Justin Strickland is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine. Dr. Strickland’s program of work focuses on developing novel interventions for substance use and substance use disorder using translationally relevant designs. His research applies behavioral economic methods to evaluate choice and decision-making mechanisms that may underlie substance use and identify targets for their reduction. He is also interested in the behavioral and pharmacological mechanisms that underlie the potential therapeutic and adverse effects of cannabinoids.

    No relevant financial disclosures

    Credits & Disclosures

    Joint Accreditation Statement

    image

    In support of improving patient care, the American Society of Addiction Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credits Available

    • Physicians: 1.00 Credit(s)
    • Nurses & NPs: 1.00 Nursing Contact Hour(s)
    • Pharmacology Hour(s): Not offered
    • PAs: 1.00 Credit(s)
    • Pharmacists: 1.00 Credit(s)
    • Interprofessional Continuing Education: 1.00 Credit(s)
    • Certified Counselors: NBCC Contact Hours Not offered
    image American Society of Addiction Medicine has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 7062. Programs that do not qualify for NBCC credit are clearly identified. American Society of Addiction Medicine is solely responsible for all aspects of the programs.

    Maintenance of Certification (MOC)/Continuing Certification Program (CCP)

    This activity is designed to meet the requirements for MOC/CCP for several primary physician boards and for state licensing CME requirements. MOC Credit is only reported and designated for ABA, ABP, ABIM, and ABS. By completing the online credit application and evaluation, the learner permits ASAM to report credits to the appropriate Board. Learn more.

    • ABA MOCA 2.0®*: 1.00 Lifelong Learning
    • ABIM MOC Points: 1.00 Medical Knowledge
    • ABP MOC: 1.00 Lifelong Learning & Self-Assessment
    • ABS Continuing Certification: 1.00 Accredited CME | 1.00 Self-Assessment

    Additionally, this activity has been designed to satisfy the requirements of the following primary physician board certification requirements. Please confirm with your individual Board.

    • American Board of Addiction Medicine (ABAM)
    • American Board of Preventative Medicine (ABPM)
    • American Board of Psychiatry and Neurology (ABPN)
    • Royal College of Physicians and Surgeons of Canada (RCPSC)

    Certificates for other professions

    All participants may request a certificate of participation upon completion of the activity and an online evaluation confirming their participation. Learners are strongly advised to contact their professional licensing board or professional association to confirm this certificate will be accepted as evidence supporting continuing education requirements.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1225.

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205.

    California Consortium of Addiction Programs and Professionals (CCAPP)

    This educational program is approved by CCAPP: #OS-20-330-1224.

    MOCA 2.0® is a trademark of the American board of Anesthesiology®. This activity contributes to the patient safety CME requirement for Part II: Lifelong Learning and Self-Assessment of the American board of Anesthesiology's (ABA) redesigned Maintenance of Certification in Anesthesiology Program® (MOCA®), known as MOCA 2.0®. Please consult the ABA website, https://www.theaba.org/, for a list of all MOCA 2.0 requirements.

    Disclosure Information

    In accordance with the disclosure policies of ASAM and Joint Accreditation, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all accredited continuing education activities. These policies include identifying and mitigating all relevant financial relationships with ineligible companies for those involved in the creation and dissemination of accredited continuing education.

    See the attached pdf for a list of disclosures.

  • Product not yet rated Contains 8 Component(s), Includes Credits

    This 1-hour and 45-minute, on-demand session from the 2024 ASAM State of the Art Course discusses tobacco use in different populations, GLP-1 use for smoking cessation, comparative effectiveness of treatment models, and more, to provide a comprehensive overview of the state of the art of treatment for nicotine use disorder.

    image

    Nicotine

    Recorded: Thursday, October 17, 2024 - Friday, October 18, 2024
    On-Demand Session

    Overview

    Smoking remains the leading cause of preventable disease and death in the US, killing more than 480,000 Americans each year. Smoking cessation is possible and can save lives. This session will discuss tobacco use in different populations, GLP-1 use for smoking cessation, comparative effectiveness of treatment models, and more, to provide a comprehensive overview of the state of the art of treatment for nicotine use disorder. 

    This session is comprised of 4 presentations and a panel that dive deep into different aspects of the overall topic.

    • Adaptive Trials for Tobacco Cessation
      This session will review clinical trials testing the development or comparative effectiveness of adaptive tobacco cessation treatment models which adapt individual cessation treatment based on user response. The session will further explore the strengths and limitations of different trial designs and assess the generalizability of adaptive treatment research findings for use in clinical practice.
    • GLP-1 Agonists for the Treatment of Nicotine Dependence and Post-Cessation Weight Management: The Skinny on Novel Anti-Obesity Medications
      Despite tremendous health benefits, smoking cessation leads to an increased consumption of highly palatable foods. As a result, the majority of former smokers gain weight after quitting. Post-cessation weight gain (PCWG) can decrease smoking cessation motivation and success, and it can have detrimental effects on metabolic health in those who do achieve abstinence. This presentation will focus on the potential utility of glucagon-like peptide 1 receptor agonists (GLP1-RA) for addressing tobacco smoking and post-cessation weight management.  The author will discuss the overall state of the science on targeting GLP-1Rs to reduce tobacco smoking and PCWG, with the primary focus on the completed and ongoing clinical trials conducted by our group. Directions for future clinical research will be provided.
    • Tobacco Use among Older Adults: A Forgotten Population
      The number of adults 65 years and older is projected to nearly double between 2012 and 2050, prompting global efforts to address the inevitable challenges of this population shift. Of concern is the parallel observation that tobacco smoking prevalence in the US and other countries has declined considerably for all age groups except for those 65 and older. Given these trends, it is likely that the absolute number of older adults who smoke will increase in the coming years. This presentation will explore these trends and address older adults' interest in quitting and cessation rates. The presentation will also expand on the recently published ASAM Criteria (4th Ed) chapter on tobacco use, focusing on older adults and harm reduction approaches.
    • Novel and Emerging Interventions for Patients Unwilling to Quit
      Smoking tobacco cigarettes is associated with premature mortality. Quitting smoking can help people gain between 3 to 10 Quality Adjusted Life Years (QALYs). However, even the best evidence-based treatments have low absolute quit rates. Repeated attempts are associated with greater success and should be encouraged. Unfortunately, some populations such as those with concurrent addictions and or mental illness are "treatment resistant". This session will present emerging evidence on novel and new interventions (e.g. brain stimulation) that could help them stop smoking cigarettes for good. In addition, this session will invite attendees to appraise the evidence for off-label use of existing treatments including combination, higher doses, extended treatment, and lower risk nicotine use guidelines.

    These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:

    • Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
    • Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
    • Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine

    This conference addresses all 6 ACGME Competencies.

    Learning Objectives

    At the end of the course, learners should be able to:

    1. Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
    2. Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
    3. Develop practical applications for integrating new and emerging science into practice.
    4. Identify gaps in the field of addiction medicine that future research can address.
    5. Create a network of colleagues and resources to support the learner's practice or form future research collaborations.

    DEA Education Requirement

    As an accredited organization named in Section 1263 of the Consolidated Appropriations Act of 2023, ASAM certifies that completion of this course meets 2 hours of the DEA requirement for 8 hours of education on substance use disorder(s).

    Registration Rates

    ASAM Learner TypeRate
    ASAM Member$29
    Non-Member$39
    Associate Member$19
    Resident Member*$19
    Student Member*$19

    *Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.

    Membership Question?  Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.

    Refunds & Cancellations

    All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.

    Registration Open: 11/01/2024 - 10/01/2027

    User Access Closed: 11/01/2027

    Instructions

    1. Click on the Contents tab to begin this activity.
    2. Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
    3. Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
    4. Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.

    Need Assistance?

    For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org

    ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.

    Peter Selby

    MBBS, CCFP, FCFP, DFASAM

    Dr. Peter Selby is a Senior Medical Consultant and Clinician Scientist at the Centre for Addiction and Mental Health (CAMH). He is the Vice-Chair, of Research, and Giblon Professor in Family Medicine Research, a University Named Professorship at the University of Toronto.  He is also the Director of the Mental Health and Addictions Division in the Department of Family and Community Medicine, University of Toronto.  His research focuses on innovative methods to understand and treat addictive behaviors and their comorbidities. He also uses technology to combine clinical medicine and public health methods to scale up and test health interventions.

     

    He has received grant funding totaling over 100 million dollars from CIHR, NIH, and the Ministry of Health and has published >150 peer-reviewed publications. He has published 6 books (including 5 edited), is the author of 31 book chapters, and has 38 research reports prepared for the government. He is the Chair of the Medical Education Council for the American Society of Addiction Medicine. Dr. Selby mentors Fellows in Addiction Medicine and Addiction Psychiatry, junior investigators, and medical students. The use of innovative methods to communicate messages makes Dr. Selby a sought-after speaker for various topics including addictive disorders, motivational interviewing, and health behavior change at individual and system levels. 

    Does Disclose - Johnson and Johnson, Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Pfizer, Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment

    Luba Yammine

    PhD, APRN, FNP-C

    Dr. Yammine,is a clinician and research scientist specializing in the treatment of substance use disorders, including tobacco, alcohol and OUD. She is a provider of medication-assisted treatment and authorized to prescribe buprenorphine to treat OUD. She is also a nationally certified Tobacco Treatment Specialist. Her treatment approach is holistic and integrates services to address addiction along with co-occurring mental and medical issues into the comprehensive care of the individual. As a researcher, Yammine is the Primary Investigator of a CCTS exenatide as a potential treatment for smoking cessation. She is also a Primary/ Co-Investigator on several Department of Defense funded projects that focus on treatments for Veterans with substance use disorders. She completed her undergraduate studies in nursing at Texas Woman’s University and Master’s and Doctoral studies at the University of Texas Health Science Center at Houston. She went on to complete postdoctoral training in addiction research at Baylor College of Medicine/Michael E. DeBakey VA Medical Center.

    Gina R. Kruse, MD, MS, MPH

    Associate Professor

    University of Colorado School of Medicine

    Dr. Gina Kruse is a physician researcher in the Division of General Internal Medicine at the University of Colorado School of Medicine. She trained in internal medicine and primary care at Massachusetts General Hospital, completed a Harvard Medical School General Internal Medicine research fellowship, earned her MPH in Clinical Effectiveness from the Harvard T.H. Chan School of Public Health followed by a post-doctoral fellowship in Cancer Prevention from the Harvard T.H. Chan School of Public Health Department of Social and Behavioral Sciences. Dr. Kruse’s research uses clinical trials, observational research, and mixed methods to test interventions and examine implementation strategies to improve the delivery of preventive services with a focus on improving tobacco cessation treatment in healthcare settings in the US and internationally. 

    No relevant financial disclosures

    Bethea (Annie) Kleykamp, PhD, MA

    Assistant Professor

    University of Maryland School of Medicine

    Bethea (Annie) Kleykamp, MA, PhD, is an Assistant Professor at the University of Maryland School of Medicine and the Director of Research and Evaluation at the Maryland Addiction Consultation Service. Dr. Kleykamp’s graduate training was in cognitive psychopharmacology, and she completed postdoctoral fellowships in behavioral pharmacology and nicotine psychopharmacology. Dr. Kleykamp’s research focuses on the impact of substance use and related policies on the growing older adult population and the importance of harm reduction. In 2011, Dr. Kleykamp chose a career trajectory off the beaten path in science writing and health policy, including positions that spanned the non-profit, for-profit, and public healthcare sectors. During this time, she also created a science writing business, BAK and Associates, which provides expert guidance on science communication and systematic review development. Despite being outside the traditional academic path, she has maintained her scholarly productivity, authoring over 75 systematic reviews, peer-reviewed publications, and popular press articles on aging, nicotine/tobacco use, opioids, chronic pain, and clinical trial design. Dr. Kleykamp is currently running a pilot trial of e-cigarettes as a harm reduction tool among older adults who smoke tobacco and are in outpatient treatment for opioid use disorder. 

    No relevant financial disclosures

    Credits & Disclosures

    Joint Accreditation Statement

    image

    In support of improving patient care, the American Society of Addiction Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credits Available

    • Physicians: 1.75 Credit(s)
    • Nurses & NPs: 1.75 Nursing Contact Hour(s)
    • Pharmacology Hour(s): .5 Hour(s)
    • PAs: 1.75 Credit(s)
    • Pharmacists: 1.75 Credit(s)
    • Interprofessional Continuing Education: 1.75 Credit(s)
    • Certified Counselors: NBCC Contact Hours Not offered
    image American Society of Addiction Medicine has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 7062. Programs that do not qualify for NBCC credit are clearly identified. American Society of Addiction Medicine is solely responsible for all aspects of the programs.

    Maintenance of Certification (MOC)/Continuing Certification Program (CCP)

    This activity is designed to meet the requirements for MOC/CCP for several primary physician boards and for state licensing CME requirements. MOC Credit is only reported and designated for ABA, ABP, ABIM, and ABS. By completing the online credit application and evaluation, the learner permits ASAM to report credits to the appropriate Board. Learn more.

    • ABA MOCA 2.0®*: 1.75 Lifelong Learning
    • ABIM MOC Points: 1.75 Medical Knowledge
    • ABP MOC: 1.75 Lifelong Learning & Self-Assessment
    • ABS Continuing Certification: 1.75 Accredited CME | 1.75 Self-Assessment

    Additionally, this activity has been designed to satisfy the requirements of the following primary physician board certification requirements. Please confirm with your individual Board.

    • American Board of Addiction Medicine (ABAM)
    • American Board of Preventative Medicine (ABPM)
    • American Board of Psychiatry and Neurology (ABPN)
    • Royal College of Physicians and Surgeons of Canada (RCPSC)

    Certificates for other professions

    All participants may request a certificate of participation upon completion of the activity and an online evaluation confirming their participation. Learners are strongly advised to contact their professional licensing board or professional association to confirm this certificate will be accepted as evidence supporting continuing education requirements.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1225.

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205.

    California Consortium of Addiction Programs and Professionals (CCAPP)

    This educational program is approved by CCAPP: #OS-20-330-1224.

    MOCA 2.0® is a trademark of the American board of Anesthesiology®. This activity contributes to the patient safety CME requirement for Part II: Lifelong Learning and Self-Assessment of the American board of Anesthesiology's (ABA) redesigned Maintenance of Certification in Anesthesiology Program® (MOCA®), known as MOCA 2.0®. Please consult the ABA website, https://www.theaba.org/, for a list of all MOCA 2.0 requirements.

    Disclosure Information

    In accordance with the disclosure policies of ASAM and Joint Accreditation, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all accredited continuing education activities. These policies include identifying and mitigating all relevant financial relationships with ineligible companies for those involved in the creation and dissemination of accredited continuing education.

    See the attached pdf for a list of disclosures.

  • Product not yet rated Contains 8 Component(s), Includes Credits

    This 2-hour, on-demand session from the 2024 ASAM State of the Art Course examines new research on AUD treatment, including spironolactone, psychedelics, GLP-1, and technology-assisted approaches.

    image

    Alcohol

    Recorded: Thursday, October 17, 2024 - Friday, October 18, 2024
    On-Demand Session

    Overview

    According to 2023 national data, 10% of individuals ages 12 and older met criteria for an alcohol use disorder (AUD) in the past year. This indicates an urgent need for effective and innovative approaches to meet the needs of this large treatment population. This session will examine new research on AUD treatment, including spironolactone, psychedelics, GLP-1, and technology-assisted approaches.

    This session is comprised of 4 presentations that deep dive into different aspects of the overall topic.

    • Spironolactone in Alcohol Addiction: A Translational Approach
      This session will review recent work conducted in animal models, including mice, rats, and non-human primates, as well as recent work in humans, including in people with alcohol use disorder, that has been conducted on (1) the relationship between aldosterone and alcohol drinking and dependence, and (2) the potential role of spironolactone in alcohol use disorder.
    • Psychedelics for the Treatment of Alcohol Use Disorder
      The session will describe  the results of completed trials of investigational psychedelic medications in the treatment to alcohol use disorder. Evidence for safety and efficacy will be evaluated, and possible mechanisms of action will be discussed based on currently available data. The prevention will also discuss possible next steps toward clinical use and safe and equitable dissemination of new treatments should they become available for clinical use.
    • Repurposing the Glucagon-Like Peptide-1 Receptor Agonist Semaglutide to Treat Alcohol Use Disorder
      Anecdotal reports of the efficacy of semaglutide and other Glucagon-Like Peptide-1 (GLP-1) receptor agonists as medical therapies for obesity have garnered widespread public attention, engendering ethical debates and leading to worldwide drug shortages.  This brief presentation will update participants about the National Institute on Drug Abuse Intramural Research Program's ongoing early phase clinical trial studying the exciting possibility of repurposing semaglutide to treat patients with alcohol use disorder.
    • Technology-Assisted Approaches to Facilitate Remotely Delivered Alcohol Use Disorder Treatment
      This session will provide an overview of recent research that has involved remotely delivered alcohol use disorder treatment. Covered topics will include the key elements of treatment delivery that can be facilitated by technology, the types of devices and their features that have been useful for this research, and results from randomized clinical trials employing these techniques. Overall, results will demonstrate that technology-assisted approaches to alcohol use disorder treatment delivery can demonstrate high degrees of efficacy while overcoming some of the treatment-access barriers associated with in-person treatments.

    These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:

    • Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
    • Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
    • Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine

    This conference addresses all 6 ACGME Competencies.

    Learning Objectives

    At the end of the course, learners should be able to:

    1. Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
    2. Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
    3. Develop practical applications for integrating new and emerging science into practice.
    4. Identify gaps in the field of addiction medicine that future research can address.
    5. Create a network of colleagues and resources to support the learner's practice or form future research collaborations.

    DEA Education Requirement

    As an accredited organization named in Section 1263 of the Consolidated Appropriations Act of 2023, ASAM certifies that completion of this course meets 2 hours of the DEA requirement for 8 hours of education on substance use disorder(s).

    Registration Rates

    ASAM Learner TypeRate
    ASAM Member$29
    Non-Member$39
    Associate Member$19
    Resident Member*$19
    Student Member*$19

    *Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.

    Membership Question?  Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.

    Refunds & Cancellations

    All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.

    Registration Open: 11/01/2024 - 10/01/2027

    User Access Closed: 11/01/2027

    Instructions

    1. Click on the Contents tab to begin this activity.
    2. Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
    3. Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
    4. Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.

    Need Assistance?

    For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org

    ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.

    Lorenzo Leggio

    MD. PhD, MSc

    Dr. Lorenzo Leggio serves as the Chief of the joint NIAAA/NIDA Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology. He received his M.D. and Ph.D. from the Catholic University of Rome, where he also completed residency and Board Certification in Internal Medicine. He received a Masters in Alcoholism from the University of Florence. He was a postdoctoral research associate in Psychiatry and Human Behavior at Brown University. In 2010, he became Assistant Professor at the Brown University Center for Alcohol and Addiction Studies (CAAS). Dr. Leggio's clinical research has been primarily focused on the treatment of alcoholism, with an emphasis on the role of feeding-related and GABAergic pathways; and on the medical consequences of alcoholism, with an emphasis on alcoholic liver disease. While at Brown, he received funding from NIH and various foundations. In 2012, Dr. Leggio joined NIAAA and NIDA as a joint Clinical Investigator and Section Chief. He is licensed and credentialed as Senior Attending Medical Staff at the NIH Clinical Center. Dr. Leggio also serves as the Associate Director for Clinical Research for the NIDA IRP Medication Development Program. Additionally, he is an Adjunct Associate Professor at the Brown University CAAS. Dr. Leggio's lab has pioneered clinical research on the role of neuroendocrine signaling in alcoholism. He has authored or co-authored over 100 peer-reviewed manuscripts and has served as reviewer for NIH study sections and other U.S. and international funding agencies. He has served as consultant for FDA advisory panels, and on the editorial boards of addiction-related journals. He has served as Chair (Clinical) of the 2016 Research Society on Alcoholism (RSA) Program Committee. Among other awards, he received the 2008 ESBRA Nordmann Award, the 2015 NIAAA Clinical Service Award, the 2016 NIAAA Mentoring Award, and the 2016 RSA Early Career Investigator Award

    No Relevant Financial Disclosures

    Michael P. Bogenschutz, MD

    Director

    NYU Langone Center for Psychedelic Medicine

    Dr. Bogenschutz is a Professor of Psychiatry at NYU Grossman School of Medicine and director of the NYU Langone Center for Psychedelic Medicine. He is an addiction psychiatrist with over 20 years of experience conducting NIH-funded research on pharmacological and behavioral treatments for addictions and co-occurring psychiatric disorders. Prior to joining the faculty at NYU Grossman School of Medicine in 2015, he was Vice-chair for Addiction Psychiatry at the University of New Mexico, where he established and directed an addiction psychiatry fellowship and for 10 years served as the PI of the Southwest Node of the NIDA Clinical Trials Network. Over the past decade he has investigated the therapeutic potential of serotonergic psychedelic drugs such as psilocybin and MDMA. He has completed two trials of psilocybin-assisted treatment for alcohol use disorder, and currently site PI for a 3-site NIDA-funded trial of psilocybin in the treatment of tobacco use disorder. He is also engaged in NIAAA-funded research on non-psychedelic pharmacotherapies, focusing on efficacy as well neural mechanisms and the use of machine learning strategies to identify likely responders.

    No relevant financial disclosures

    Stephanie T. Weiss

    MD, PhD

    Stephanie T. Weiss, MD PhD is the staff Research Physician serving the Translational Addiction Medicine Branch (TAMB) of the NIDA Intramural Research Program. After earning a Ph.D. in pharmaceutical chemistry, Dr. Weiss received her medical degree from Cleveland Clinic Lerner College of Medicine. She is board certified in emergency medicine and medical toxicology, a subspecialty that cares for patients with poisonings, environmental exposures, and overdoses. She subsequently completed a second fellowship in addiction medicine research and was selected to participate in the Boston University Research in Addiction Medicine Scholars Program prior to joining NIDA. Dr. Weiss assumes responsibility for providing optimal, safe, and ethical care to study participants and clinical support toward the TAMB mission conducting inpatient and outpatient proof-of-concept human laboratory studies. Her research interests include novel psychoactive substances, medication misuse, and improving interpretation of urine drug testing.

    No relevant financial disclosures.

    Mikhail N. Koffarnus, PhD

    Associate Professor

    University of Kentucky

    Mikhail Koffarnus, PhD, is an Associate Professor and Vice Chair for Research in the Department of Family and Community Medicine at the University of Kentucky College of Medicine. He received his BA in Psychology from the University of Wisconsin - Eau Claire and his MS and PhD in Biopsychology at the University of Michigan. He also completed a pre-doctoral fellowship at the National Institute on Drug Abuse and a post-doctoral fellowship in the Behavioral Pharmacology Research Unit at Johns Hopkins University. He currently sits on the editorial board of two academic journals and is a Fellow of the American Psychological Association. He was also recently elected President of the Society for Psychopharmacology and Substance Use (American Psychological Association Division 28) to take effect in 2025. His research focuses on understanding decision-making and valuation processes that perpetuate substance use, as well as the translation of that understanding to applied endpoints such as tobacco regulatory policy and substance use treatment methodologies. Current projects are investigating mobile health approaches to remote delivery of behavioral alcohol use disorder treatment and estimating the impact of proposed tobacco product regulations in Appalachian Kentucky as a function of rurality.

    No relevant financial disclosures

    Credits & Disclosures

    Joint Accreditation Statement

    image

    In support of improving patient care, the American Society of Addiction Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credits Available

    • Physicians: 2 Credit(s)
    • Nurses & NPs: 2 Nursing Contact Hour(s)
    • Pharmacology Hour(s): 1 Hour(s)
    • PAs: 2 Credit(s)
    • Pharmacists: 2 Credit(s)
    • Interprofessional Continuing Education: 2 Credit(s)
    • Certified Counselors: NBCC Contact Hours Not offered
    image American Society of Addiction Medicine has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 7062. Programs that do not qualify for NBCC credit are clearly identified. American Society of Addiction Medicine is solely responsible for all aspects of the programs.

    Maintenance of Certification (MOC)/Continuing Certification Program (CCP)

    This activity is designed to meet the requirements for MOC/CCP for several primary physician boards and for state licensing CME requirements. MOC Credit is only reported and designated for ABA, ABP, ABIM, and ABS. By completing the online credit application and evaluation, the learner permits ASAM to report credits to the appropriate Board. Learn more.

    • ABA MOCA 2.0®*: 2 Lifelong Learning
    • ABIM MOC Points: 2 Medical Knowledge
    • ABP MOC: 2 Lifelong Learning & Self-Assessment
    • ABS Continuing Certification: 2 Accredited CME | 2 Self-Assessment

    Additionally, this activity has been designed to satisfy the requirements of the following primary physician board certification requirements. Please confirm with your individual Board.

    • American Board of Addiction Medicine (ABAM)
    • American Board of Preventative Medicine (ABPM)
    • American Board of Psychiatry and Neurology (ABPN)
    • Royal College of Physicians and Surgeons of Canada (RCPSC)

    Certificates for other professions

    All participants may request a certificate of participation upon completion of the activity and an online evaluation confirming their participation. Learners are strongly advised to contact their professional licensing board or professional association to confirm this certificate will be accepted as evidence supporting continuing education requirements.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1225.

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205.

    California Consortium of Addiction Programs and Professionals (CCAPP)

    This educational program is approved by CCAPP: #OS-20-330-1224.

    MOCA 2.0® is a trademark of the American board of Anesthesiology®. This activity contributes to the patient safety CME requirement for Part II: Lifelong Learning and Self-Assessment of the American board of Anesthesiology's (ABA) redesigned Maintenance of Certification in Anesthesiology Program® (MOCA®), known as MOCA 2.0®. Please consult the ABA website, https://www.theaba.org/, for a list of all MOCA 2.0 requirements.

    Disclosure Information

    In accordance with the disclosure policies of ASAM and Joint Accreditation, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all accredited continuing education activities. These policies include identifying and mitigating all relevant financial relationships with ineligible companies for those involved in the creation and dissemination of accredited continuing education.

    See the attached pdf for a list of disclosures.

  • Product not yet rated Contains 8 Component(s), Includes Credits

    This 1-hour and 45-minute, on-demand session from the 2024 ASAM State of the Art Course discusses new approaches such as tele-harm reduction, brain stimulation, and more.

    image

    Innovations in Technology

    Recorded: Thursday, October 17, 2024 - Friday, October 18, 2024
    On-Demand Session

    Overview

    Recent innovations in addiction treatment technology are transforming clinical care. These advancements provide novel, personalized treatment options, facilitate real-time communication with healthcare providers, and promote engagement in recovery and harm reduction. This session will discuss new approaches such as tele-harm reduction, brain stimulation, and more.

    This session is comprised of 4 presentations that deep dive into different aspects of the overall topic.

    • Harnessing Digital Health in the Assessment and Treatment of Substance Use Disorders
      This session explores the role of digital health technologies in the assessment and treatment of substance use disorders. Attendees will learn about innovative digital tools that enhance screening accuracy, personalize treatment, and improve patient engagement. The discussion will cover the benefits, challenges, and ethical considerations of using digital health in clinical practice, as well as its potential to transform substance use care. 
    • Tele-Harm Reduction
      This session will introduce Tele-Harm Reduction (THR) as a crucial and innovative tool towards ending the HIV epidemic. THR leverages telehealth technology to deliver comprehensive care within syringe services programs (SSPs). T-SHARP is a clinical trial that aims to improve HIV outcomes among people who inject drugs (PWID). The trial evaluates the efficacy of this telehealth intervention in achieving viral suppression, initiating medications for opioid use disorder (MOUD), and curing hepatitis C. By bridging the digital divide and meeting PWID where they are, T-SHARP seeks to transform HIV care delivery and improve clinical outcomes.
    • Randomized Repetitive Transcranial Magnetic Stimulation Trial for Smoking Cessation
      A comparison of 1 Hz rTMS over the medial frontal cortex and 10 Hz rTMS over the dorsolateral prefrontal cortex was completed in healthy smokers. Results showed that 10 Hz rTMS reduced cigarette consumption more than 1 Hz rTMS as well as sham TMS. 10 Hz treatment increased brain activity in the lateral prefrontal cortex and decreased brain activity in the medial frontal cortex. The study demonstrates that 10 Hz rTMS stimulation of the dorsolateral prefrontal cortex in an executive control circuit may be better for developing brain stimulation treatment than 1Hz rTMS of the medial orbitofrontal cortex in a medial reward circuit.
    • Primary and Secondary Findings from the NIDA CTN ADAPT-2 Trial in Relation to the Treatment of Methamphetamine Use Disorder
      This session will delve into the cutting-edge research and treatment options for stimulant use disorders. Participants will learn about the latest pharmacotherapy developments and the significance of biomarker research in enhancing treatment efficacy. The discussion will also cover the challenges faced in treating stimulant use disorders and propose innovative solutions. Overall, the session aims to provide a comprehensive understanding of the evolving landscape of stimulant use disorder treatments.

    These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:

    • Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
    • Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
    • Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine

    This conference addresses all 6 ACGME Competencies.

    Learning Objectives

    At the end of the course, learners should be able to:

    1. Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
    2. Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
    3. Develop practical applications for integrating new and emerging science into practice.
    4. Identify gaps in the field of addiction medicine that future research can address.
    5. Create a network of colleagues and resources to support the learner's practice or form future research collaborations.

    DEA Education Requirement

    As an accredited organization named in Section 1263 of the Consolidated Appropriations Act of 2023, ASAM certifies that completion of this course meets 2 hours of the DEA requirement for 8 hours of education on substance use disorder(s).

    Registration Rates

    ASAM Learner TypeRate
    ASAM Member$29
    Non-Member$39
    Associate Member$19
    Resident Member*$19
    Student Member*$19

    *Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.

    Membership Question?  Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.

    Refunds & Cancellations

    All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.

    Registration Open: 11/01/2024 - 10/01/2027

    User Access Closed: 11/01/2027

    Instructions

    1. Click on the Contents tab to begin this activity.
    2. Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
    3. Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
    4. Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.

    Need Assistance?

    For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org

    ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.

    Madhukar H. Trivedi

    MD

    Madhukar Trivedi is Professor of Psychiatry, Chief of the Division of Mood Disorders, and Director of the Center for Depression Research and Clinical Care at UT Southwestern Medical Center. He earned his MBBS and MS in Baroda, India, completing his residencies in Psychiatry at University General Hospital, Baroda, India and Henry Ford Hospital, Detroit, Michigan. He completed his fellowship at UT Southwestern, where he now serves as Betty Jo Hay Distinguished Chair in Mental Health and Julie K. Hersh Chair for Depression Research and Clinical Care. Certified by the American Board of Psychiatry and Neurology, Dr. Trivedi is an established clinical and translational researcher with extensive experience serving as PI and Co-PI on several single and multi-site clinical trials funded by NIH, foundations and industry sponsors.

    Dr. Trivedi’s research over the last 25 years has focused on understanding the neurobiology and psychology of depression and bipolar disorder, with a particular focus on developing an empirical basis for improving treatment of depression. Dr. Trivedi and his team have been involved in many of the pivotal studies involving the establishment of efficacy of antidepressant treatments (medications, psychotherapy, exercise, complimentary treatments, devices, etc.), examining next steps in treatment resistant depression to develop algorithms and guidelines, and developing and validating biomarkers in order to reach the goal of precision medicine for mood disorders. Among his most notable studies are the Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care (EMBARC) trial, Combining Medications to Enhance Depression Outcomes (CO-MED) trial, Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, and the Texas Resilience Against Depression (T-RAD) study.

    Does Disclose: Alkermes; monetary payment; Consulting Alto Neuroscience Inc; monetary payment & stock investments; Stockholder / Scientific Advisory Axsome Therapeutics, Inc.; N/A; Consulting Biogen MA Inc; monetary payment; Consulting Circular Genomics Inc.; stock investments; Consulting / Stockholder GH Research Limited; monetary payment; Consulting GreenLight VitalSign6; stock investments; Stockholder / Scientific Advisory Heading Health, Inc; n/a; Scientific Advisory; Janssen; n/a; Consulting Legion Health; stock investment; Stockholder / Scientific Advisory Mind Medicine (MindMed) Inc.; n/a; Consulting Neurocrine Biosciences Inc; n/a; Consulting Orexo US Inc; monetary payment; Consulting / Scientific Advisory Otsuka America Pharmaceutical, Inc.; monetary payment; Consulting Otsuka Canada Pharmaceutical Inc; monetary payment; Consulting Otsuka Pharmaceutical Development & Commercialization, Inc.; monetary payment; Consulting; Sage Therapeutics; monetary payment; Consulting Takeda Pharmaceutical Company Ltd.; n/a; Consutling WebMD; monetary payment; Consulting Sparian Biosciences; n/a; Consulting

    Dr. Lisa Marsch, PhD

    Professor of Psychiatry, Center for Technology and Behavioral Health; Geisel School of Medicine at Dartmouth College

    Lisa A. Marsch, PhD is the Director of the Center for Technology and Behavioral Health (a NIDA-funded P30 Center of Excellence) at Dartmouth College. With funding from NIH, she has led a line of research focused on the development and evaluation of cutting-edge, technology-based (mobile and Internet-delivered) interventions focused on substance abuse treatment among youth and adults, HIV prevention among substance-using youth and adults, substance abuse prevention among children and adolescents, as well as other behavioral health issues. 

    These technology-based therapeutic tools reflect an integration of science-based behavioral interventions with evidence-based informational technologies. This work has been conducted in a variety of settings, including physician offices, substance abuse treatment programs, criminal justice settings, primary care settings, educational settings and via the Internet.

    Teresa A. Chueng, MD, MPH

    Assistant Professor of Clinical Medicine

    University of Miami Miller School of Medicine

    Dr. Teresa Chueng is a public health physician trained in internal medicine and infectious disease; she joined University of Miami Miller School of Medicine as an Assistant Professor of Clinical Medicine in 2022.

    Dr. Chueng is passionate about the intersection of infectious diseases with addiction medicine. She is faculty at the IDEA Exchange, Florida's first syringe services program where she provides low-barrier care to people with substance use disorder. She is also Associate Director of the Severe Injection Related Infections (SIRI) Team at Jackson Memorial Hospital, an inpatient infectious disease and addiction consultation service that offers integrated and holistic care for people who use drugs. She co-leads the women's clinic at IDEA Exchange to provide medications for substance use disorder, wound care, contraception, and sexually transmitted infection treatment. Dr. Chueng also is a core faculty member in the Department of Medicine, where she co-runs the addiction medicine rotation to train the next generation of internal medicine residents.

    No relevant financial disclosures

    Xingbao Li, MD, MS

    Associate Professor

    Medical University of South Carolina

    Dr. Li earned his M.D. and M.S. in China. In 2019, Dr. Li completed his Master of Science in Clinical Research at the Medical University of South Carolina (MUSC). He has been working in the Brain Stimulation Lab since 2000. He is also a faculty member at the Center for Biomedical Imaging (CBI) at MUSC. His research interests include transcranial magnetic stimulation (TMS), functional MRI, and combining TMS and functional MRI techniques in neuropsychiatry, especially in substance abuse. Dr. Li is a pioneer in using TMS for smoking cessation. US NIH has awarded Dr. Li in the development of addiction therapy since 2014. Now, Dr. Li is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at MUSC.

    No relevant financial disclosures

    Credits & Disclosures

    Joint Accreditation Statement

    image

    In support of improving patient care, the American Society of Addiction Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credits Available

    • Physicians: 1.75 Credit(s)
    • Nurses & NPs: 1.75 Nursing Contact Hour(s)
    • Pharmacology Hour(s): 0.5 Hour(s)
    • PAs: 1.75 Credit(s)
    • Pharmacists: 1.75 Credit(s)
    • Interprofessional Continuing Education: 1.75 Credit(s)
    • Certified Counselors: NBCC Contact Hours Not offered
    image American Society of Addiction Medicine has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 7062. Programs that do not qualify for NBCC credit are clearly identified. American Society of Addiction Medicine is solely responsible for all aspects of the programs.

    Maintenance of Certification (MOC)/Continuing Certification Program (CCP)

    This activity is designed to meet the requirements for MOC/CCP for several primary physician boards and for state licensing CME requirements. MOC Credit is only reported and designated for ABA, ABP, ABIM, and ABS. By completing the online credit application and evaluation, the learner permits ASAM to report credits to the appropriate Board. Learn more.

    • ABA MOCA 2.0®*: 1.75 Lifelong Learning
    • ABIM MOC Points: 1.75 Medical Knowledge
    • ABP MOC: 1.75 Lifelong Learning & Self-Assessment
    • ABS Continuing Certification: 1.75 Accredited CME | 1.75 Self-Assessment

    Additionally, this activity has been designed to satisfy the requirements of the following primary physician board certification requirements. Please confirm with your individual Board.

    • American Board of Addiction Medicine (ABAM)
    • American Board of Preventative Medicine (ABPM)
    • American Board of Psychiatry and Neurology (ABPN)
    • Royal College of Physicians and Surgeons of Canada (RCPSC)

    Certificates for other professions

    All participants may request a certificate of participation upon completion of the activity and an online evaluation confirming their participation. Learners are strongly advised to contact their professional licensing board or professional association to confirm this certificate will be accepted as evidence supporting continuing education requirements.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1225.

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205.

    California Consortium of Addiction Programs and Professionals (CCAPP)

    This educational program is approved by CCAPP: #OS-20-330-1224.

    MOCA 2.0® is a trademark of the American board of Anesthesiology®. This activity contributes to the patient safety CME requirement for Part II: Lifelong Learning and Self-Assessment of the American board of Anesthesiology's (ABA) redesigned Maintenance of Certification in Anesthesiology Program® (MOCA®), known as MOCA 2.0®. Please consult the ABA website, https://www.theaba.org/, for a list of all MOCA 2.0 requirements.

    Disclosure Information

    In accordance with the disclosure policies of ASAM and Joint Accreditation, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all accredited continuing education activities. These policies include identifying and mitigating all relevant financial relationships with ineligible companies for those involved in the creation and dissemination of accredited continuing education.

    See the attached pdf for a list of disclosures.

  • Product not yet rated Contains 8 Component(s), Includes Credits

    This 1-hour and 45-minute, on-demand session from the 2024 ASAM State of the Art Course explores a contextual model of addiction recovery and delve into different tools that may support individuals in maintaining recovery including contingency management, expanded medication access, and culturally attuned interventions.

    image

    Maintaining Recovery

    Recorded: Thursday, October 17, 2024 - Friday, October 18, 2024
    On-Demand Session

    Overview

    Addiction is a chronic medical disease, and recovery looks different from traditional acute care models. This session will explore a contextual model of addiction recovery and delve into different tools that may support individuals in maintaining recovery including contingency management, expanded medication access, and culturally attuned interventions.

    This session is comprised of 4 presentations that deep dive into different aspects of the overall topic.

    • A Contextual Model of Addiction Recovery
      This session will review models of addiction and propose a more central role for the context as a determinant of behavior in addiction and recovery. Models of addiction, though reductive in nature, are communicated broadly to the public and impact perceptions of addiction, scientific priorities, clinical practice, and policy decisions. Brain disease, moral, and choice models account for some, but not all, of the phenomenology of addiction, and are mechanistically limited in scope. This session will outline contextual models of addiction and recovery, review empirical evidence supporting the role of context, and outline potential benefits of a contextual model at  the level of the individual and society in the areas of science, clinical practice, and policy.
    • Contingency Management
      This session will review the goals of contingency management and the principles that underly the treatment approach.  This session will discuss the key metrics or elements that make up a contingency management intervention.  This session will review the evidence base that supports this treatment approach, with a particular focus on adolescents and the unique aspects to consider when using contingency management with youth.
    • Expanding Methadone Access Across New York State
      The session will review changes in federal regulations to methadone treatment for opioid use disorder, discuss data evaluating the impact of regulatory changes on the delivery of methadone treatment and on opioid use disorder outcomes, and present new strategies that leverage regulatory changes to expand methadone treatment for opioid use disorder.
    • Imani Breakthrough Program: A Culturally-Attuned, Faith-Based Opioid Recovery Intervention for Black and LatinX Communities
      This session will discuss the Imani Breakthrough Project. Imani is a community delivered, faith-based, person-centered, culturally informed, harm reduction recovery program that provides an integrated approach to engaging Black and Latinx people and other vulnerable individuals to substance use supports, by focusing on dimensions of holistic health and wellness, reconnecting people to their sense of community, and by providing harm reduction and telemedicine and referrals for MAT.  Come learn about ways we can effectively collaborate with churches and people with lived/living experiences.

    These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:

    • Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
    • Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
    • Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine

    This conference addresses all 6 ACGME Competencies.

    Learning Objectives

    At the end of the course, learners should be able to:

    1. Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
    2. Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
    3. Develop practical applications for integrating new and emerging science into practice.
    4. Identify gaps in the field of addiction medicine that future research can address.
    5. Create a network of colleagues and resources to support the learner's practice or form future research collaborations.

    DEA Education Requirement

    As an accredited organization named in Section 1263 of the Consolidated Appropriations Act of 2023, ASAM certifies that completion of this course meets 2 hours of the DEA requirement for 8 hours of education on substance use disorder(s).

    Registration Rates

    ASAM Learner TypeRate
    ASAM Member$29
    Non-Member$39
    Associate Member$19
    Resident Member*$19
    Student Member*$19

    *Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.

    Membership Question?  Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.

    Refunds & Cancellations

    All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.

    Registration Open: 11/01/2024 - 10/01/2027

    User Access Closed: 11/01/2027

    Instructions

    1. Click on the Contents tab to begin this activity.
    2. Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
    3. Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
    4. Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.

    Need Assistance?

    For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org

    ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.

    Chinazo Cunningham

    MD, MS

    Dr. Chinazo Cunningham is Commissioner of the NY State Office of Addiction Services and Supports. In this role, she oversees substance use prevention, care, treatment, and policies across NY state. She is a physician trained in internal medicine and addiction medicine and has spent over 20 years providing care, developing programs, and conducting research with people who use drugs. For decades, she has collaborated with community-based harm reduction organizations. Her work has focused on improving access to care, utilization of health care services, and health outcomes. Dr. Cunningham has authored scores of peer-reviewed manuscripts, been the principal investigator on numerous federally funded grants, served on many scientific advisory committees, and received several mentoring awards.

    Pamela Matson, PhD, MPH

    Associate Professor of Pediatrics

    Johns Hopkins University School of Medicine

    Pamela Matson, PhD, MPH is the Research Director of the Adolescent Medicine Fellowship Program at Johns Hopkins Medicine.

    Samuel F. Acuff, PhD

    Postdoctoral Fellow

    Recovery Research Institute, Center for Addiction Medicine, Department of Psychiatry, Massachusetts General Hospital

    Dr. Samuel Acuff has a PhD in Clinical Psychology and is currently a postdoctoral research fellow at Massachusetts General Hospital’s Recovery Research Institute and a Clinical Fellow at Harvard Medical School. Dr. Acuff completed his doctoral training in the psychology department at the University of Memphis and his clinical psychology internship at the Warren Alpert Medical School at Brown University. His research is informed by behavioral economics and seeks to illuminate environmental and contextual influences on the development of and recovery from substance use disorders, with a particular focus on social factors. 

    No relevant financial disclosures

    Chyrell D. Bellamy, PhD, MSW

    Professor and Director

    Program for Recovery and Community Health & DEIA, Yale Center for Clinical Investigation

    Chyrell D. Bellamy, PhD, MSW, is a Professor at Yale School of Medicine, Department of Psychiatry; Director of Yale Program for Recovery and Community Health (PRCH); and Associate Director of Diversity, Equity, Inclusion and Accessibility, Yale Center for Clinical Investigation (YCCI). At PRCH, she is the Director of Peer Support Services & Research and Director of the Lived Experience Transformational Leadership Academy (LET(s)Lead). Her research and practice examine sociocultural experiences and pathways to wellness and recovery in the prevention and treatment of mental illness and addictions; peer support effectiveness; organization and leadership transformation with a focus on antiracism, cultural humility, and responsiveness; lived experience leadership; and community-based participatory research/co-design methods. 

    Dr. Bellamy has served on more than 42 NIH, PCORI, SAMHSA, CT DMHAS, RWJ, and private foundation-funded grants nationally and internationally. Her work on developing leaders and researchers doing participatory work in research is known and respected globally. She has mentored/collaborated with scholars from the USA and internationally on career awards from NIH, NIDILLR, Fulbright, Diversity Supplements, and K awards. She is a co-founder and director of the International Yale Lived Experience Transformational Leadership Academy (LET(s)Lead), where she has worked with fellows from New Zealand, Canada, Toronto, Australia, and the USA on leadership and development projects. 
    Dr. Bellamy's personal experience is not just a part of her work, it's the heart of it. She openly identifies as a person with lived/living experience of multiple marginalized and minoritized identities, including mental illness, trauma, and addictions. This personal connection to her work is what makes her a compassionate and effective frontline service provider, clinician, social worker, community educator and organizer, trainer, program evaluator, and community and academic researcher in the health and behavioral health fields. Her extensive recognition in the field, including various federal and state grants for her work on peer support and community-based participatory development of interventions, and prestigious awards such as the Pearl Johnson Advocacy Award from the National Association for Rights Protection and Advocacy, The Steve Harrington Award from the National Association of Peer Support, the inaugural Celia Brown Advocacy Award from the Alliance for Rights and Recovery (formerly NYAPRS), and the Museum of African American Addiction, Treatment, and Recovery Hall of Fame Award, is a testament to her expertise and leadership. 

    No relevant financial disclosures

    Credits & Disclosures

    Joint Accreditation Statement

    In support of improving patient care, the American Society of Addiction Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.image

    Credits Available

    • Physicians: 1.75 Credit(s)
    • Nurses & NPs: 1.75 Nursing Contact Hour(s)
    • Pharmacology Hour(s): 0.5 Hour(s)
    • PAs: 1.75 Credit(s)
    • Pharmacists: 1.75 Credit(s)
    • Interprofessional Continuing Education: 1.75 Credit(s)
    • Certified Counselors: NBCC Contact Hours Not offered

    Maintenance of Certification (MOC)/Continuing Certification Program (CCP)

    This activity is designed to meet the requirements for MOC/CCP for several primary physician boards and for state licensing CME requirements. MOC Credit is only reported and designated for ABA, ABP, ABIM, and ABS. By completing the online credit application and evaluation, the learner permits ASAM to report credits to the appropriate Board. Learn more.

    • ABA MOCA 2.0®*: 1.75 Lifelong Learning
    • ABIM MOC Points: 1.75 Medical Knowledge
    • ABP MOC: 1.75 Lifelong Learning & Self-Assessment
    • ABS Continuing Certification: 1.75 Accredited CME | 1.75 Self-Assessment

    Additionally, this activity has been designed to satisfy the requirements of the following primary physician board certification requirements. Please confirm with your individual Board.

    • American Board of Addiction Medicine (ABAM)
    • American Board of Preventative Medicine (ABPM)
    • American Board of Psychiatry and Neurology (ABPN)
    • Royal College of Physicians and Surgeons of Canada (RCPSC)

    Certificates for other professions

    All participants may request a certificate of participation upon completion of the activity and an online evaluation confirming their participation. Learners are strongly advised to contact their professional licensing board or professional association to confirm this certificate will be accepted as evidence supporting continuing education requirements.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1225.

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205.

    California Consortium of Addiction Programs and Professionals (CCAPP)

    This educational program is approved by CCAPP: #OS-20-330-1224.

    Disclosure Information

    In accordance with the disclosure policies of ASAM and Joint Accreditation, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all accredited continuing education activities. These policies include identifying and mitigating all relevant financial relationships with ineligible companies for those involved in the creation and dissemination of accredited continuing education.

    See the attached pdf for a list of disclosures.

    image American Society of Addiction Medicine has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 7062. Programs that do not qualify for NBCC credit are clearly identified. American Society of Addiction Medicine is solely responsible for all aspects of the programs.

    MOCA 2.0® is a trademark of the American board of Anesthesiology®. This activity contributes to the patient safety CME requirement for Part II: Lifelong Learning and Self-Assessment of the American board of Anesthesiology's (ABA) redesigned Maintenance of Certification in Anesthesiology Program® (MOCA®), known as MOCA 2.0®. Please consult the ABA website, https://www.theaba.org/, for a list of all MOCA 2.0 requirements.

    The complete list of disclosures and designation statements are linked below.

  • Product not yet rated Contains 8 Component(s), Includes Credits

    This 1-hour, 45-minute, on-demand session from the 2024 ASAM State of the Art Course discusses research and treatment approaches for common co-occurring disorders, such as HIV, hepatitis, infectious diseases, and stress and trauma.

    image

    Comorbidities

    Recorded: Thursday, October 17, 2024 - Friday, October 18, 2024
    On-Demand Session

    Overview

    Patients receiving addiction treatment frequently present with medical and psychological conditions that can greatly affect their overall well-being. This 1-hour, 45-minute, on-demand session from the 2024 ASAM State of the Art Course discusses research and treatment approaches for common co-occurring disorders, such as HIV, hepatitis, infectious diseases, and stress and trauma.

    This session is comprised of 4 presentations that deep dive into different aspects of the overall topic.

    • Early Liver Transplantation for Severe Alcoholic Hepatitis
      The most common cause of liver failure requiring liver transplantation in the United States is excessive alcohol consumption. Without liver transplantation, patients with Alcohol Associated Hepatitis (AAH) that fail medical management have survival rates of ~30%. U.S. Transplant teams encountered substantial increases in the prevalence of AAH in younger, sicker patients with short sobriety subsequent to the COVID-19 Pandemic. This session will describe two new outpatient programs developed to improve treatment adherence and reduce relapse in this high-risk population; 1. "Total Recovery", a 12-week program exclusively for liver transplant patients with Alcohol Use Disorders; 2. "The Integrated Liver Transplant Engagement and Recovery Network (ILEARN)", an NIH-funded, co-located program for Post-Liver Transplant Management of Alcohol Use Disorders.
    • Implementing a Peer-Supported, Integrated Strategy for Substance Use Disorder Care in an Outpatient Infectious Disease Clinic is Associated with Improved Patient Outcomes
      The RESTORE service (REcovery in Specialty care Through medication and OutREach) was established in January 2019 at Johns Hopkins Hospital in Baltimore City, Maryland, to improve access to SUD treatment and recovery services among patients with multiple comorbidities, including HIV and HCV. This session will describe the experiences and preliminary outcomes of a co-located substance use disorder (SUD) treatment and recovery service within an outpatient infectious disease specialty clinic. The presentation will cover the program funding, design, implementation and research findings. Despite the disruptions that COVID-19 pandemic caused, the high retention rates and low overdose risk observed in the multicomponent program demonstrated the effectiveness of the program.
    • HIV & Addiction: Long-Acting Injectable Therapy for People with HIV
      This session will review long acting cabotegravir/rilpivirine (LA-CAB/RPV) including the drug classes, dosing, and administration. It will review the current evidence around its use in people who inject drugs (PWID) with comorbid HIV. The session will also describe in detail a current clinic's implementation of LA-CAB/RPV in PWID including in those not virally suppressed.
    • The PROUD Study: Promoting Resilience for Medicaid Members with Opioid Use Disorder During Climate and Environmental Stressors
      This session will review findings of the PROUD (Promoting Resilience Among Medicaid Members with Opioid Use Disorder) study. This community partnered, participatory study assessed experiences of care for Medicaid members with opioid use disorder faced with environmental stressors such as hurricanes, floods, and pandemic surges. The presenter will review policy opportunities which may mitigate interruptions in care during major environmental stressors.

    These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:

    • Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
    • Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
    • Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine

    This conference addresses all 6 ACGME Competencies.

    Learning Objectives

    At the end of the course, learners should be able to:

    1. Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
    2. Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
    3. Develop practical applications for integrating new and emerging science into practice.
    4. Identify gaps in the field of addiction medicine that future research can address.
    5. Create a network of colleagues and resources to support the learner's practice or form future research collaborations.

    Registration Rates

    ASAM Learner TypeRate
    ASAM Member$29
    Non-Member$39
    Associate Member$19
    Resident Member*$19
    Student Member*$19

    *Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.

    Membership Question?  Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.

    Refunds & Cancellations

    All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.

    Registration Deadline: 10/1/2027

    Instructions

    1. Click on the Contents tab to begin this activity.
    2. Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
    3. Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
    4. Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.

    Need Assistance?

    For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org

    ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.

    Robert M. Weinrieb, MD

    Chief Psychiatric Consultant and Program Director Consultation-Liaison Psychiatry Fellowship

    Penn Transplant Institute & University of Pennsylvania, Perelman School of Medicine

    Dr. Weinrieb came to Philadelphia in 1991 after completing his residency in adult psychiatry at St. Vincent’s Hospital of NY Medical College in Greenwich Village, NY. He then completed a Department of Veteran’s Affairs Fellowship in Addiction Medicine from the Penn/VA Center for the Study of Addictions in 1993. His first faculty position was Medical Director of the Penn Treatment Research Center, which he directed for 7 years. He teaches a Doctoring Course to medical students, served on the Penn Institutional Review Board for Human Studies, the Penn Medical School Student Standards Committee and the Standing Conflict of Interest Committee of the University of Pennsylvania.

    From his work as the consultant psychiatrist for the liver transplant team of the Hospital of the University of Pennsylvania, which he began in 1995, Dr. Weinrieb became an NIH and VAMC grant funded investigator focusing his interests on the study and treatment of psychiatric and addictive disorders in solid organ transplant patients. His primary clinical and research interests focus on liver transplantation for people with Alcohol Use Disorders. Dr. Weinrieb has been the recipient of a number of research and teaching awards, including the Lindback Award for Distinguished Teaching from the University of Pennsylvania. He was the Director of Consultation-Liaison Psychiatry and the Psychiatric Emergency Evaluation Center of the Hospital of the University of Pennsylvania from 2006-2016 and is currently Chief Psychiatric Consultant for the Penn Transplant Institute and continues as the founder and Program Director of an ACGME accredited Fellowship in Consultation-Liaison Psychiatry at the Hospital of the University of Pennsylvania/Penn VAMC, Perelman School of Medicine. Dr. Weinrieb also founded and directs one of the only outpatient psychiatric clinics exclusively for transplant patients in the United States that treats patients longitudinally. He thoroughly enjoys teaching and mentoring undergraduates, medical students, dental students, advanced practice nursing students, psychiatry and neurology residents.

    Credits & Disclosures

    Joint Accreditation Statement

    image

    In support of improving patient care, the American Society of Addiction Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credits Available

    • Physicians: 1.75 Credit(s)
    • Nurses & NPs: 1.75 Nursing Contact Hour(s)
    • Pharmacology Hour(s): 0.5 Hour(s)
    • PAs: 1.75 Credit(s)
    • Pharmacists: 1.75 Credit(s)
    • Interprofessional Continuing Education: 1.75 Credit(s)
    • Certified Counselors: NBCC Contact Hours Not offered
    image American Society of Addiction Medicine has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 7062. Programs that do not qualify for NBCC credit are clearly identified. American Society of Addiction Medicine is solely responsible for all aspects of the programs.

    Maintenance of Certification (MOC)/Continuing Certification Program (CCP)

    This activity is designed to meet the requirements for MOC/CCP for several primary physician boards and for state licensing CME requirements. MOC Credit is only reported and designated for ABA, ABP, ABIM, and ABS. By completing the online credit application and evaluation, the learner permits ASAM to report credits to the appropriate Board. Learn more.

    • ABA MOCA 2.0®*: 1.75 Lifelong Learning
    • ABIM MOC Points: 1.75 Medical Knowledge
    • ABP MOC: 1.75 Lifelong Learning & Self-Assessment
    • ABS Continuing Certification: 1.75 Accredited CME | 1.75 Self-Assessment

    Additionally, this activity has been designed to satisfy the requirements of the following primary physician board certification requirements. Please confirm with your individual Board.

    • American Board of Addiction Medicine (ABAM)
    • American Board of Preventative Medicine (ABPM)
    • American Board of Psychiatry and Neurology (ABPN)
    • Royal College of Physicians and Surgeons of Canada (RCPSC)

    Certificates for other professions

    All participants may request a certificate of participation upon completion of the activity and an online evaluation confirming their participation. Learners are strongly advised to contact their professional licensing board or professional association to confirm this certificate will be accepted as evidence supporting continuing education requirements.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1225.

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205.

    California Consortium of Addiction Programs and Professionals (CCAPP)

    This educational program is approved by CCAPP: #OS-20-330-1224.

    MOCA 2.0® is a trademark of the American board of Anesthesiology®. This activity contributes to the patient safety CME requirement for Part II: Lifelong Learning and Self-Assessment of the American board of Anesthesiology's (ABA) redesigned Maintenance of Certification in Anesthesiology Program® (MOCA®), known as MOCA 2.0®. Please consult the ABA website, https://www.theaba.org/, for a list of all MOCA 2.0 requirements.

    Disclosure Information

    In accordance with the disclosure policies of ASAM and Joint Accreditation, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all accredited continuing education activities. These policies include identifying and mitigating all relevant financial relationships with ineligible companies for those involved in the creation and dissemination of accredited continuing education.

    See the attached pdf for a list of disclosures.

  • Product not yet rated Contains 8 Component(s), Includes Credits

    This 2-hour, on-demand session from the 2024 ASAM State of the Art Course focuses on the complexities of initiation, exploring the critical phases of initiating and discontinuing addiction treatment and highlighting both established best practices and novel ways of implementing treatment interventions.

    image

    Initiation & Discontinuation

    Recorded: Thursday, October 17, 2024 - Friday, October 18, 2024
    On-Demand Session

    Overview

    Focusing on the complexities of initiation, this 2-hour, on-demand session from the 2024 ASAM State of the Art Course explores the critical phases of initiating and discontinuing addiction treatment, highlighting both established best practices and novel ways of implementing treatment interventions. Learners will review common challenges and learn about unique settings for induction.

    This session is comprised of 4 presentations that deep dive into different aspects of the overall topic.

    • Overcoming Challenges to Initiation of Extended-Release Naltrexone for Treating Opioid Use Disorder: Findings from the HEAL-Initiative NIDA Clinical Trials Network SWIFT Trial
      This session will provide an overview of the evidence regarding the effectiveness and safety of XR-naltrexone in the treatment of opioid use disorder. It will address the various challenges that community-based treatment programs face in implementing XR-naltrexone, including barriers related to patient initiation and provider training. Additionally, the presentation will describe a rapid initiation procedure for XR-naltrexone in patients actively using opioids, that has been shown to reduce the time to treatment initiation while maintaining safety and efficacy. This approach aims to improve access to and utilization of this important treatment option within community settings.
    • Shared Decision-Making and Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: Practical Tools from the SWIFT Trial
      This session will cover the findings of the CTN-0097 SWIFT study, which demonstrated the effectiveness and safety of a rapid method of initiation of injection naltrexone among patients with opioid use disorder admitted to inpatient/residential treatment, using mainly non-opioid medications to combat withdrawal and low dose titration of oral naltrexone prior to naltrexone injection. This aims to make initiation of injection naltrexone more feasible within the timeframe of typical short-term inpatient stays. The session will also describe a shared decision-making tool developed for SWIFT to guide discussion between clinicians and patients about choice of medication treatment for opioid use disorder, encouraging initiation of one of the effective medications to reduce risk of relapse and overdose.
    • Implementation Considerations for Emergency Department-Based Buprenorphine Induction for Opioid Use Disorder
      Emergency Departments are increasingly recognized as a unique touchpoint for patient access to treatment for opioid (OUD), although the provision of evidence-based treatments for OUD is underutilized. Innovations in formulations and approach to OUD medications for patients who can be safely transitioned to community partners are evolving, as are strategies to implement programs to provide OUD care. This session will review strategies and rationale for initiating buprenorphine in the emergency department including the use of high dose and injectable formulations, and review data from a recently completed nation-wide study of a 7-day injectable formulation. Strategies for implementing and building a program to evidence-based OUD care will be reviewed as well.
    • Physician-Delegated Unobserved Induction with Buprenorphine in Pharmacies
      Most Americans live within 5 miles of a pharmacy, and pharmacists are highly skilled healthcare professionals who provide counseling and dispense life-saving medication—including buprenorphine and methadone--to patients on a daily basis. Pharmacists can administer injectable medications and can be trained to more actively support patients with substance use disorder. Nearly every state has the capacity to provide pharmacist collaborative care models or to adopt pharmacist-led models as a component of much needed expansions of the behavioral health workforce. This session will review key legal and policy structures surrounding pharmacy-based care, present results and implications from a trial of unobserved induction with buprenorphine in pharmacies and consider prospects for delivery models of pharmacy-based methadone for opioid use disorder in community pharmacies.

    These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:

    • Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
    • Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
    • Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine

    This conference addresses all 6 ACGME Competencies.

    Learning Objectives

    At the end of the course, learners should be able to:

    1. Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
    2. Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
    3. Develop practical applications for integrating new and emerging science into practice.
    4. Identify gaps in the field of addiction medicine that future research can address.
    5. Create a network of colleagues and resources to support the learner's practice or form future research collaborations.

    DEA Education Requirement

    As an accredited organization named in Section 1263 of the Consolidated Appropriations Act of 2023, ASAM certifies that completion of this course meets 2 hours of the DEA requirement for 8 hours of education on substance use disorder(s).

    Registration Rates

    ASAM Learner TypeRate
    ASAM Member$29
    Non-Member$39
    Associate Member$19
    Resident Member*$19
    Student Member*$19

    *Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.

    Membership Question?  Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.

    Refunds & Cancellations

    All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.

    Registration Open: 11/01/2024 - 10/01/2027

    User Access Closed: 11/01/2027

    Instructions

    1. Click on the Contents tab to begin this activity.
    2. Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
    3. Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
    4. Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.

    Need Assistance?

    For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org

    ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.

    Adam Bisaga

    Professor of Clinical Psychiatry

    Columbia University College of Physicians and Surgeons

    Dr. Adam Bisaga is a Professor of Clinical Psychiatry at Columbia University College of Physicians and Surgeons and a Research Scientist at New York State Psychiatric Institute. His NIDA-funded research is focused on development and implementation of new medications and treatment protocols to treat opioid and other substance use disorders. Dr. Bisaga is a member of UN Expert Panel. He contributed to UN and WHO addiction treatment guidances and conducts trainings and addiction treatment program developments internationally. Dr. Bisaga authored more than 100 of peer-reviewed articles, several book chapters, and a book “Overcoming Opioid Addiction“ written for professional and lay audiences. In his commitment to medical education Dr. Bisaga serves as co-director of the SAMHSA-supported “Providers’ Clinical Support System (PCSS)” a national initiative that fosters training of providers and the implementation of effective treatments for opioid use disorders and pain management. His expertise is recognized globally, he is a member of UN Office of Drugs and Crime Expert Panel and a WHO consultant and actively collaborates with United Nations agencies to train healthcare providers and develop international treatment guidelines and programs. Additionally, Dr. Bisaga is at the forefront of integrating technology in addiction healthcare as the Medical Director of Ophelia, a telehealth company specializing in the treatment of opioid use disorder.

    Edward Nunes

    MD

    Dr. Nunes is a Professor of Psychiatry, and Principal Investigator of the Greater New York Node of the National Institute on Drug Abuse (NIDA) clinical Trials Network as well as other NIDA funded studies on behavioral and medication treatments for substance dependence and related psychiatric disorders. Interests and ongoing studies include treatments for cocaine dependence in general, heroin and other opioid dependence, for nicotine dependence in general, and for addicted patients with co-occurring psychiatric disorders including depression, and post-traumatic stress disorder. Types of treatment under study include medication treatments (naltrexone, buprenorphine, mirtazapine) as well as behavioral and psychotherapeutic approaches and computer-delivered treatments. Dr. Nunes also studies the challenges involved in implementing evidence-based treatments for substance use disorders in real-world community-based treatments settings. Dr. Nunes also serves on the American Board of Addiction Medicine, Co-Chair of the Columbia/ New York State Psychiatric Institute's Institutional Review Board, and has been appointed to the National Advisory Council on Drug Abuse.

    Kathryn Hawk, MD, MHS

    Associate Professor

    Yale University

    Kathryn Hawk, MD, MHS is an attending physician in the Yale New Haven Hospital Emergency Department and an Associate Professor in the Department of Emergency Medicine, the Yale School of Public Health and the Program in Addiction Medicine. She was a National Institute on Drug Abuse (NIDA) K12 sponsored Drug use, Addiction and HIV Research (DAHRS) Scholar, and is board certified in emergency and addiction medicine. She completed her residency training and research fellowship in the Yale University Department of Emergency Medicine. Her research primarily focuses on the design, testing and implementation of evidence based-care for ED patients with substance use disorders, with an emphasis on initiating medications for opioid and alcohol use disorder in the ED and maximizing effective linkage to ongoing treatment using innovative strategies. Her research on quality improvement and reducing opioid-associated mortality through data linkages, implementation-facilitation ED-initiated buprenorphine for opioid use disorder, initiating treatment for alcohol use disorder in the ED and the dissemination of evidence-based best practices for care of patients with addiction has been funded by NIDA, the Centers for Disease Control and Prevention (CDC), Emergency Medicine Foundation (EMF), Foundation for Opioid Response (FORE), and the National Institute on Alcohol Abuse and Alcoholism (NIAAA).

    Traci Green

    PhD, MSc

    Dr. Green is Deputy Director of the Boston Medical Center Injury Prevention Center and Associate Professor of Emergency Medicine and Epidemiology at the Warren Alpert School of Medicine at Brown University. She is an epidemiologist whose research focuses on drug abuse, addiction, and injury. She earned a Master of Science in Epidemiology and Biostatistics from McGill University and a PhD in Epidemiology from Yale University. She helped design the ASI-MV®, a real-time illicit and prescription drug abuse surveillance system developed by Inflexxion, Inc. Dr. Green helped co-found www.prescribetoprevent.org, chairs the Drug Overdose Prevention and Rescue Coalition for the Rhode Island Department of Health, and serves as an advisor to the Rhode Island Governor on addiction and overdose. Her research is supported by the Centers for Disease Control and Prevention, the National Institute on Drug Abuse, the Agency for Healthcare Research and Quality, the Patient Centered Outcomes Research Institute, and the Department of Justice.

    Credits & Disclosures

    Joint Accreditation Statement

    image

    In support of improving patient care, the American Society of Addiction Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credits Available

    • Physicians: 2 Credit(s)
    • Nurses & NPs: 2 Nursing Contact Hour(s)
    • Pharmacology Hour(s): 1.75 Hour(s)
    • PAs: 2 Credit(s)
    • Pharmacists: 2 Credit(s)
    • Interprofessional Continuing Education: 2 Credit(s)
    • Certified Counselors: NBCC Contact Hours Not offered
    image American Society of Addiction Medicine has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 7062. Programs that do not qualify for NBCC credit are clearly identified. American Society of Addiction Medicine is solely responsible for all aspects of the programs.

    Maintenance of Certification (MOC)/Continuing Certification Program (CCP)

    This activity is designed to meet the requirements for MOC/CCP for several primary physician boards and for state licensing CME requirements. MOC Credit is only reported and designated for ABA, ABP, ABIM, and ABS. By completing the online credit application and evaluation, the learner permits ASAM to report credits to the appropriate Board. Learn more.

    • ABA MOCA 2.0®*: 2 Lifelong Learning
    • ABIM MOC Points: 2 Medical Knowledge
    • ABP MOC: 2 Lifelong Learning & Self-Assessment
    • ABS Continuing Certification: 2 Accredited CME | 2 Self-Assessment

    Additionally, this activity has been designed to satisfy the requirements of the following primary physician board certification requirements. Please confirm with your individual Board.

    • American Board of Addiction Medicine (ABAM)
    • American Board of Preventative Medicine (ABPM)
    • American Board of Psychiatry and Neurology (ABPN)
    • Royal College of Physicians and Surgeons of Canada (RCPSC)

    Certificates for other professions

    All participants may request a certificate of participation upon completion of the activity and an online evaluation confirming their participation. Learners are strongly advised to contact their professional licensing board or professional association to confirm this certificate will be accepted as evidence supporting continuing education requirements.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1225.

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205.

    California Consortium of Addiction Programs and Professionals (CCAPP)

    This educational program is approved by CCAPP: #OS-20-330-1224.

    MOCA 2.0® is a trademark of the American board of Anesthesiology®. This activity contributes to the patient safety CME requirement for Part II: Lifelong Learning and Self-Assessment of the American board of Anesthesiology's (ABA) redesigned Maintenance of Certification in Anesthesiology Program® (MOCA®), known as MOCA 2.0®. Please consult the ABA website, https://www.theaba.org/, for a list of all MOCA 2.0 requirements.

    Disclosure Information

    In accordance with the disclosure policies of ASAM and Joint Accreditation, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all accredited continuing education activities. These policies include identifying and mitigating all relevant financial relationships with ineligible companies for those involved in the creation and dissemination of accredited continuing education.

    See the attached pdf for a list of disclosures.